East River BioSolutions has received a $224,566 grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) to advance the development of laboratory tools that can aid in the study of idiopathic pulmonary fibrosis (IPF). Development of effective therapies for IPF…
A mutation associated with the mucous-producing gene MUC5B, a known genetic risk factor for idiopathic pulmonary fibrosis (IPF), also is prevalent in rheumatoid arthritis patients with interstitial lung disease (ILD), according to a study led by researchers from the University of Colorado School of Medicine. The study, “MUC5B Promoter…
Mesenchymal stem cells derived from the bone marrow of people with idiopathic pulmonary fibrosis (IPF) perform basic cell functions, like growing and dividing, more poorly than do these cells from healthy people of the same age, a study reports. The study, “Senescence of bone marrow-derived mesenchymal stem cells from…
The Pulmonary Fibrosis Foundation (PFF) is now accepting applications for a new program, called PFF Scholars, that aims to support and further develop promising researchers working in the field of pulmonary fibrosis (PF). The PFF Scholars program was designed to provide emerging researchers with financial resources to conduct or…
The Pulmonary Fibrosis Foundation (PFF) created an educational website to increase awareness about this disease, with a goal of promoting earlier diagnosis among pulmonary fibrosis (PF) patients. The website includes a video explaining the disease and outlining possible causes, stories from people with the disease, and offers a downloadable Pulmonary Fibrosis…
Researchers have uncovered an immunological mechanism that underlies fibrosis in different lung conditions, including sarcoidosis and idiopathic pulmonary fibrosis (IPF), a study reports. In mouse models of pulmonary fibrosis (PF), the study also demonstrated…
Pharmaxis’ first small molecule inhibitor of LOXL2 (lysyl oxidase like 2), an enzyme that promotes fibrosis in the lungs of idiopathic pulmonary fibrosis (IPF) patients, was found safe and well-tolerated in healthy volunteers participating in a Phase 1 trial, the company announced. Additionally, treatment with the LOXL2 inhibitor, called…
Treatment with Esbriet (pirfenidone) can effectively benefit patients with idiopathic pulmonary fibrosis (IPF) who have more advanced lung function impairment, by preventing a decline in exercise capacity and worsening of shortness of breath (dyspnea). Those findings, taken from additional analysis of Phase 3 clinical trial data, were discussed…
Half a year has gone by since disgraced pharma executive Martin Shkreli was sentenced to seven years in federal prison for securities and wire fraud while heading San Diego-based Retrophin. As founder and CEO of another company (then known as Turing Pharmaceuticals), in late 2015 Shkreli bought the rights…
Ofev, an approved therapy for idiopathic pulmonary fibrosis (IPF), can prevent the progression of squamous cell carcinoma in the lungs associated with IPF, a case study reports. The study, “Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis” was published in the journal…
Get regular updates to your inbox.
